She Faced Rejection and Still Rose: The Inspiring Journey of Sibongile Sambo Raising Confident Girls in a Globalised World Exploring Culture through Travel: Why Every Woman Should Experience Africa Why Women Must Be at the Center of Global Space Innovation Dr. Irehobhude Iyioha Assumes UNESCO Chair on Health Race and Human Right Lab Queens: 12 Female Researchers Driving Real World Impact

New Early Breast Cancer Drug to Be Made Available in Singapore Via Special Access Program

A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore from today via a Special Access Program. The drug, NERLYNX (neratinib) is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy. NERLYNX has been shown to significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients.1 The greatest benefit was observed in women who were also hormone-receptor positive (HR+) and treated within 12 months following completion of trastuzumab-based adjuvant therapy. Their five-year risk of recurrence or death was reduced by 42%. In these patients, invasive disease-free survival (iDFS) was 90.8% in the patients treated with neratinib, compared with 85.7% in those receiving placebo (hazard ratio = 0.58; 95% CI: 0.41−0.82; p = 0.002). ST Asia Chief Executive Officer Mr. Carlo Montagner said a formal registration decision was not…